Skip to main content
. 2023 Aug 2;12(5):2703–2712. doi: 10.1007/s40123-023-00779-w

Table 2.

Change in best-corrected visual acuity, central choroidal thickness, and central subfield macular thickness in patient population after the initial switch to intravitreal faricimab

Parameters Pre-treatment with IVF Post-treatment with IVF Difference (post − pre) P-value
LogMAR BCVA (SD)a 0.34 (0.37) 0.36 (0.40) 0.016 (0.13) 0.29
CST, µm (SD)a 242 (72) 242 (82) 0.13 (65) 0.99
CCT, µm (SD)a 189 (98) 179 (97) − 10 (18)a  < 0.0001

aPaired t-test